Natixis Advisors LLC Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Natixis Advisors LLC boosted its position in Stevanato Group S.p.A. (NYSE:STVN) by 5.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,128 shares of the company’s stock after purchasing an additional 2,785 shares during the quarter. Natixis Advisors LLC’s holdings in Stevanato Group were worth $1,179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Van Berkom & Associates Inc. purchased a new position in shares of Stevanato Group during the fourth quarter worth about $39,000. PNC Financial Services Group Inc. lifted its position in Stevanato Group by 1,457.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock valued at $123,000 after purchasing an additional 5,291 shares during the last quarter. US Bancorp DE grew its stake in Stevanato Group by 17.9% in the 4th quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after buying an additional 1,295 shares in the last quarter. Marco Investment Management LLC bought a new position in shares of Stevanato Group in the 4th quarter worth $203,000. Finally, Hardy Reed LLC raised its position in shares of Stevanato Group by 8.2% during the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after buying an additional 840 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Morgan Stanley reiterated an “equal weight” rating and set a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. UBS Group dropped their target price on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research report on Friday, March 7th. Wolfe Research began coverage on shares of Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price target on the stock. Finally, Bank of America boosted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of €25.70 ($27.63).

Stevanato Group Price Performance

STVN opened at €21.26 ($22.86) on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The stock’s 50 day simple moving average is €21.03 and its 200 day simple moving average is €20.59. The firm has a market cap of $6.44 billion, a price-to-earnings ratio of 45.23, a PEG ratio of 7.18 and a beta of 0.60. Stevanato Group S.p.A. has a 1 year low of €16.56 ($17.81) and a 1 year high of €33.49 ($36.01).

Stevanato Group (NYSE:STVN) last issued its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €352.68 million for the quarter, compared to analysts’ expectations of €346.26 million. As a group, analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.